Search
Helping to shape Europe’s clinical trials landscape: EHA selected for ACT EU advisory group
Improving the design, efficiency and effectiveness of clinical trials is the objective of the Accelerating Clinical Trials in the European Union (ACT EU) initiative.
Read moreHematopoietic stem cells: New results to be presented at the 18th Congress of the EHA
During ageing, this fine-tuned regulatory network may become altered, leading to abnormal HSC regulation. The functional quality of HSCs decreases with age partly due to an accumulation of damaged DNA, leading to an increased incidence of hematological malignancies.
Read moreEU commissioner Tonio Borg: 'we will continue to improve the life of people suffering from Thalassaemia'
Today, May 8, is International Thalassemia Day. Today, we seek to enhance the awareness and knowledge of thalassemia and other hemoglobin disorders.
Invitation: “Can EU citizens afford their medicines? The economic crisis and access to medicines in Europe“
For more information, please find the full invitation here
Read moreEU funding crucial in allowing medical researchers across member states to collaborate in the development of new treatments
In an article published in Science|Business, Prof.
Read moreEHA-SWG Scientific Meeting on Red Cell and Iron Metabolism Defects: From Basic Science to Clinical Case Application
Dates: October 12-14, 2023
Location: Budapest, Hungary
Chairs: A Taher & A Iolascon
Collaborating SWG: EHA Specialized Working Group on Red Cells and Iron
Registration is closed
RegistrationRegistration is closed. Visit this page for more information.
The European Hematology Association (EHA) announces an Invitation to Tender (ITT) for PCO services for the EHA Annual Congress
The European Hematology Association (EHA) is pleased to inform the conference and meeting community that it will release an Invitation To Tender (ITT) for the appointment of a Professional Conference Organizer (PCO) for the EHA Congress in 2023.
Read moreThe root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.
Read moreMeet Robert Hills, our August volunteer of the month
Can you tell us what you do for EHA and when you started?
I’m a relatively recent volunteer for EHA, as I only started working with them on their Clinical Research Training in Hematology (CRTH) program in 2016.
Meet Robert Hills, our August volunteer of the month
Can you tell us what you do for EHA and when you started?
I’m a relatively recent volunteer for EHA, as I only started working with them on their Clinical Research Training in Hematology (CRTH) program in 2016.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- »